Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2006-06-16 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
独立董事关于调整公司股权分置改革方案之独立意见
Regulatory Filings Classification · 90% confidence The document is an independent director's opinion on the adjustment of the company's equity split reform plan, referencing regulatory guidelines and company articles. It discusses the adjustment of share compensation and cash distribution to shareholders. The document is a formal opinion related to corporate governance and shareholder rights, not a financial report, earnings release, or announcement of voting results. It does not contain financial statements or earnings data. It is a regulatory or governance-related filing but does not fit the Governance Information (CGR) category exactly, as it is an independent director's opinion on a specific corporate action. Given the nature and length, it is best classified under Regulatory Filings (RNS) as a formal regulatory announcement that does not fit other categories.
2006-06-16 Chinese
股权分置改革说明书（修订稿）
Regulatory Filings Classification · 95% confidence The document is titled "股权分置改革说明书（修订稿全文）" which translates to "Equity Split Reform Explanation Document (Revised Full Text)". It is issued by Wuhan Mayinglong Pharmaceutical Group Co., Ltd. The content includes detailed explanations about the company's equity structure, history of shareholding changes, financial data summaries, and the equity split reform plan. It discusses the negotiation and approval process among shareholders, the impact on governance and future development, and includes legal and sponsor opinions. The document is lengthy (15,000 characters) and contains substantive financial data and detailed corporate governance and shareholder structure information. It is not a brief announcement or a certification letter but a comprehensive explanatory document about a corporate restructuring event related to share reform. This type of document is a detailed explanatory statement related to a corporate restructuring event, which aligns with the category of Regulatory Filings (RNS) because it does not fit the definitions of Annual Report, Audit Report, or other specific categories. It is not a proxy solicitation or voting results announcement, nor is it a capital change announcement in the narrow sense of new share issuance or stock splits. It is a regulatory filing explaining the equity split reform in detail, including financial data and shareholder structure, but not a formal financial report or earnings release. Therefore, the best classification is Regulatory Filings (RNS).
2006-06-16 Chinese
股权分置改革之补充保荐意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed supplementary sponsorship opinion letter regarding the equity split reform of Wuhan Mayinglong Pharmaceutical Group Co., Ltd. It includes an independent opinion from sponsoring institutions, detailed explanations of the equity split reform adjustments, impact on shareholders, and the rationale behind the pricing arrangements. The document is not a general announcement but a formal, detailed opinion and evaluation related to a corporate restructuring event involving share capital and shareholder rights. It is not an annual or interim financial report, nor a simple announcement or voting result. It is a specialized report related to capital restructuring and financing activities, specifically the equity split reform and related share compensation arrangements. Therefore, the document best fits the category of Capital/Financing Update (CAP). The document length (4681 characters) and content confirm it is a substantive report, not just an announcement or certification.
2006-06-16 Chinese
股权分置改革说明书摘要（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "股权分置改革说明书（修订稿摘要）" which translates to "Equity Split Reform Explanation Document (Revised Summary)". It is issued by Wuhan Mayinglong Pharmaceutical Group Co., Ltd. and details a comprehensive plan for equity split reform involving non-tradable shares and tradable shares, including the arrangement of compensation, shareholder meetings, voting requirements, and legal and regulatory compliance. The document includes detailed financial and structural information about the equity reform, shareholder commitments, risk disclosures, and legal opinions. It is a detailed explanatory document related to a corporate restructuring event concerning share capital and shareholder rights, not a general annual or quarterly financial report, nor a simple announcement or voting result. It is not a proxy solicitation or remuneration report. The document is lengthy (over 10,000 characters) and contains substantive content about the reform plan and its implementation. This type of document is best classified under Capital/Financing Update (CAP) because it relates to changes in the company's capital structure and financing arrangements through the equity split reform process.
2006-06-16 Chinese
股权分置改革的补充法律意见书
Regulatory Filings Classification · 95% confidence The document is a supplementary legal opinion letter issued by a law firm regarding the adjustment of a company's equity split reform plan. It discusses legal compliance, procedural approvals, and adjustments to the equity reform scheme. It is not a financial report, earnings release, or management discussion. It is a legal opinion related to corporate restructuring and equity reform, which does not fit into categories like Annual Report, Interim Report, or Capital/Financing Update. It is also not a regulatory announcement or certification. Given the nature of the document as a legal opinion letter on a corporate equity reform, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not neatly fit into other specific categories.
2006-06-16 Chinese
股权分置改革之保荐意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed independent sponsor opinion letter regarding a company's equity split reform (股权分置改革) for Wuhan Mayinglong Pharmaceutical Group Co., Ltd. It includes legal references, detailed analysis of the reform plan, shareholder structure changes, risk assessments, and sponsor declarations. The document is issued by sponsoring securities firms and is focused on the equity split reform process, its rationale, and its impact on shareholders. It is not a general annual or quarterly report, nor an earnings release or call transcript. It is not a proxy solicitation or voting results announcement. The document is a formal sponsor opinion letter related to a capital restructuring event, specifically the equity split reform, which is a type of capital/financing update. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (9659 characters) and content confirm it is a full opinion report, not just an announcement or certification, so it is not RPA or RNS.
2006-06-07 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.